U.K. government responds to drugmaker appeals.
Review focuses on two new Alzheimer's drugs.
Potential implications for healthcare funding.
Briefing: U.K. to Reassess Cost-Effectiveness of Alzheimer's Drugs
Strategic angle: Following successful appeals from drugmakers, the U.K. is reviewing the cost-effectiveness of two new Alzheimer's treatments.